izingantibodiesareunabletoinhibitdirectviral
(203) 791-6766.
cell-to-cell spread of human cytomegalovirus. Virology 2013, 444,
Present Address 140−147.
†
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury
Road, Ridgefield, Connecticut 06877, United States.
Notes
T■he authors declare no competing financial interest.
ACKNOWLEDGMENTS
This manuscript is dedicated to the memory of our friend and
colleague Louis Morency. The authors thank Annick Gauthier
for stimulating discussion and George Kukolj, Peter White,
BrunoSimoneau,Fred́ eŕicVaillancourt,CedrickxGodbout,Jeff
O’Meara, Maria Ribadeneira, Pierre Bonneau, Michael
Cordingley, Richard Bethell, and Paul Edwards for their
■leadership and support.
ABBREVIATIONS
H■CMV,humancytomegalovirus;HTS,high-throughputscreen
REFERENCES
(1) Reviewed recently in: Griffiths, P.; Baraniak, I.; Reeves, M. The
pathogenesis of human cytomegalovirus. J. Pathol. 2015, 235, 288−
297.
(2) Recently reviewed in: Romero, P. P.; Blanco, P.; Gimeń ez, E.;
Solano,C.;Navarro,D.Anupdateonthemanagementandprevention
of cytomegalovirus infection following allogeneic hematopoietic stem
celltransplantation. Future Virol.2015,10,113−134.
(3) Fu, T.-M.; An, Z.; Wang, D. Progress on pursuit of human
cytomegalovirus vaccines for prevention of congenital infection and
disease. Vaccine 2014,32, 2525−2533.
(4)EC50valuesareminimallytheaverageofduplicateexperiments
performed in triplicate. Individual EC50 values were within 3-fold of
eachother90%ofthetimefortheqPCRassay(n=62compounds),
99%ofthetimefortheCPEassay(n=171compounds